



GIACONDA'S PICOCONDA LICENSED BY REDHILL

- **Licensing brings significant cash injection into Giaconda**
- **Giaconda stands to benefit further if the product is successfully commercialised**

Sydney, NSW, [28 February] 2014 - Giaconda Limited ("Giaconda") today announced that RedHill Biopharma Ltd ("RedHill" ; NASDAQ: RDHL) has entered into a worldwide license agreement with Salix Pharmaceuticals for Picoconda and rights to other purgative developments. Giaconda sold Picoconda to RedHill under an asset purchase agreement along with its proprietary products Myoconda and Heliconda in 2010. Giaconda will receive an upfront payment of US\$1,000,000 plus 20% of the net royalties paid to RedHill by Salix. In addition, Giaconda will receive 20% of future milestones.

Giaconda's Chief Executive Officer and acting Chairman, Mr Patrick McLean, said: "This deal on Picoconda demonstrates RedHill's ability to commercialize the therapies that they acquired from us back in 2010. It is a major milestone for both RedHill and Giaconda and promises a bright future for Giaconda's shareholders.

RedHill's Chief Executive Officer, Mr Dror Ben-Asher, said: "We are happy with the transaction between RedHill and Salix and hope it helps to make Giaconda's shareholders feel good about entrusting RedHill with Myoconda, Heliconda and Picoconda (respectively entitled: RHB-104, RHB-105 and RHB-106) and that RedHill is the right "home" for those important products. We remain highly committed to the development of the products acquired from Giaconda and have made significant progress with the licensing of RHB-106 to Salix, and with both RHB-104 and RHB-105 currently in Phase III studies in the U.S

For further information please contact:

Patrick McLean
CEO and Acting Chairman
Giaconda Limited

T: +1 (514) 937-5440

mclean278@hotmail.com

SKYPE: patricklockie4

Marcus Connor
Company Secretary
Giaconda Limited

T: +972 528 0875

marcus.connor@c-legal.com.au

GIACONDA LIMITED

Ground Floor, 44 East Street, Five Dock NSW 2046 Phone: [612] 9370 0069 Fax: [612] 9712 1469
email: info@giacondalimited.com ABN 68 108 088 517 www.giacondalimited.com